Benzinga | Oct 8, 2020 09:16AM EDT

Ampio Pharma Highlights Publication Of Scientific Manuscript On Effects Of Ampion On Peripheral Blood Monocytes

Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the publication of a scientific manuscript on Ampion(tm) effects on peripheral blood monocytes ("PBMC") in a preprint report (Ampion suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC, DOI: https://doi.org/10.21203/rs.3.rs-86515/v1).



In this report, evidence is provided that Ampion reduces pro-inflammatory cytokine release by activating the immunoregulatory transcription factors PPAR? and AhR. In addition, data indicates that Ampion suppresses NF-?B and STAT1? pro-inflammatory pathways, suggesting that Ampion acts through these mechanisms to decrease pro-inflammatory transcription factor activity and subsequent inflammatory cytokine production.

This publication adds to the growing evidence of the important anti-inflammatory activities of Ampion in various inflammation related conditions, including the dysregulated immune response observed in severe COVID-19 infected patients. A recurring theme across all clinical trials with Ampion, including our recent Phase I trial for intravenous ("IV") Ampion treatment for COVID-19 patients, is that this anti-inflammatory biologic has been safe and well-tolerated with no serious drug related adverse events. https://ampiopharma.com/news/ampio-reports-positive-results-in-early-trial-for-iv-ampion-treatment-in-covid-19-patients/